Appointment comes amid resignation of Marie-France Tschudin from company executive committee.
Effective Sept. 15, Marie-France Tschudin, president, innovative medicines international, chief commercial officer, will be leaving Novartis. In her place, the company has added Patrick Horber with the title of president, international. Currently, Horber works as SVP and president, immunology, AbbVie.
A native of Switzerland with an MD from the University of Zurich, Horber will join Novartis with over 20 years of experience in the biopharma field.
"As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress,” said Horber, in a company press release. “I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”
Reference: Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis. Novartis. September 6, 2023. Accessed September 6, 2023. https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.